bioMérieux Stock: Drops 2.77% at Close Following Forecast Downgrade
bioMérieux's stock fell this Thursday at the close, down 2.77% to 105.40 euros. This decline came two days after the company's downward revision of its annual guidance. The CAC 40 index also dropped by 1.36% on the day. However, the stock's annual performance remains positive, up 2.33% over the past twelve months.
Current Trading Session Overview
bioMérieux closed at 105.40 euros, down from 108.40 euros on Wednesday, marking a correction of 2.77%. Over the past seven days, the stock has accumulated a loss of 5.89%, with the decline intensifying over three months, down 15.48%. The broader market remains under pressure, with the CAC 40 losing 1.36% today. Nonetheless, the stock's annual performance has increased by 2.33%, which is significantly lower than the 7.53% posted by the benchmark index over twelve months. Trading volumes remained moderate, with only 0.15% of the capital traded on Thursday, indicating diminished investor interest in the stock. With a monthly volatility of 7.13%, the stock shows controlled movement amplitude, characterized by a beta of 0.03 indicating a very low correlation with market movements.
Revised Forecasts for 2025
On Tuesday, November 4, bioMérieux published its forecasts for 2025, marked by a significant downward recalibration. The company now expects organic growth of 5.5% to 6.5%, compared to the previously anticipated 6% to 7.5%. This revision is explained by a respiratory season that is proving to be later than expected. In the first nine months of 2025, bioMérieux reported sales of 2.99 billion euros, with organic growth of 7.3%, remaining aligned with its initial outlook. The four drivers of the strategic plan GO•28 are accelerating with a growth of 9%. The SPOTFIRE range recorded a remarkable surge of 114%, while the non-respiratory BIOFIRE panels grew by 10%. In contrast, the respiratory BIOFIRE panels declined by 8%, and China experienced a double-digit decline. bioMérieux confirms its target for growth in contributive current operating income of 12% to 18% at constant exchange rates.
Technical Analysis
From a technical standpoint, bioMérieux is positioned below its two anchoring moving averages. The price of 105.40 euros remains below the 50-day moving average of 113.55 euros and the 200-day moving average of 117.11 euros, indicating a bearish structure. The stock is trading within the Bollinger Bands (115.38 / 107.38), indicating contained volatility. The RSI is at 43, a neutral position with no predominant bullish or bearish trend. The MACD remains in negative territory at -0.81, complemented by a signal line at -0.53. A technical support is forming around 108.40 euros (Wednesday's price), while a resistance is emerging at 116.60 euros.
